Can 18F-FDG PET/CT predict recurrence in patients with cutaneous malignant melanoma?

被引:15
|
作者
Kang, S. [1 ]
Ahn, B. -C. [1 ]
Hong, C. M. [1 ]
Song, B. -I. [1 ]
Lee, H. J. [1 ]
Jeong, S. Y. [1 ]
Lee, S. -W. [1 ]
Lee, S. J. [2 ]
机构
[1] Kyungpook Natl Univ, Sch Med, Dept Nucl Med, Taegu 700721, South Korea
[2] Kyungpook Natl Univ, Sch Med, Dept Dermatol, Taegu 700721, South Korea
来源
NUKLEARMEDIZIN-NUCLEAR MEDICINE | 2011年 / 50卷 / 03期
关键词
Cutaneous malignant melanoma; F-18-FDG PET/CT; predicting recurrence; standardized uptake value; POSITRON-EMISSION-TOMOGRAPHY; PANCREATIC-CARCINOMA; METASTATIC MELANOMA; PROGNOSTIC VALUE; STANDARD UPTAKE; ROI DEFINITION; FLOW-CYTOMETRY; NECK TUMORS; FDG UPTAKE; CANCER;
D O I
10.3413/Nukmed-0356-10-09
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The aim of this study was to evaluate the prognostic significance of maximum standardized uptake value (SUVmax) of primary cutaneous malignant melanoma (CMM) lesions by F-18-FDG positron emission tomography/computerized tomography (PET/CT) in terms of recurrence. Patients, methods: 37 CMM patients (17 men, mean age: 61.7 +/- 13.6 years) that underwent PET/CT at presentation were enrolled in this study. Recurrence was determined by histological confirmation or by radiological and clinical follow-up for at least 8 months after curative surgery. Clinical variables such as age, sex, clinical stage, and primary lesion location, thickness, and ulceration, and SUVmax values were analyzed with respect to their usefulness for predicting recurrence. Results: SUVmax was found to be significantly higher in patients with ulceration of primary lesion of CMM (p = 0.004) and in patients with a stage >= III (p < 0.000). Patients that experience recurrence had a significantly higher mean SUVmax value (4.9 +/- 2.9) than patients who did not (2.1 +/- 1.5, p = 0.024). ROC analysis showed that a SUVmax cut-off value 2.2 had high sensitivity (88.9%) and specificity (67.9%) for predicting recurrence. Kaplan-Meier analysis identified ulceration of primary lesion (p = 0.034), stage >= III (p = 0.019) and SUVmax >= 2.2 (p = 0.002) as predictors of recurrence. However, Cox proportional-hazards analysis showed that only SUVmax (p = 0.025, relative risk 11.063) significantly predicted recurrence. Conclusion: Preoperative SUVmax of primary lesion was found to be the most potent predictor of recurrence in CMM patient. Patients with high SUV max of primary lesion should be followed meticulously for recurrence.
引用
收藏
页码:116 / 121
页数:6
相关论文
共 50 条
  • [21] 18F-FDG PET/CT can be used to predict progression in smoldering multiple myeloma patients
    Visram, Alissa
    Rajkumar, Vincent
    Kumar, Shaji
    Broski, Stephen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S134 - S134
  • [22] Utility of the PET-CT scan with 18F-FDG in a case of choroid melanoma recurrence
    Sabate, M.
    Garcia, J. R.
    Valls, E.
    Moragas, M.
    Soler, M.
    Riera, E.
    Lomena, F.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2012, 31 (03): : 167 - 168
  • [23] 18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer
    Crivellaro, Cinzia
    Signorelli, Mauro
    Guerra, Luca
    De Ponti, Elena
    Buda, Alessandro
    Dolci, Carlotta
    Pirovano, Cecilia
    Todde, Sergio
    Fruscio, Robert
    Messa, Cristina
    GYNECOLOGIC ONCOLOGY, 2012, 127 (01) : 131 - 135
  • [24] Pretreatment 18F-FDG PET/CT radiomics predict recurrence in patients treated with radiotherapy for cervical cancer
    Yousefirizi, Fereshteh
    Harsini, Sara
    Holloway, Caroline
    Tonseth, Pete
    Alexander, Abraham
    Saboury, Babak
    Uribe, Carlos
    Rahmim, Arman
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [25] Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?
    Christos Sachpekidis
    Lionel Larribère
    Annette Kopp-Schneider
    Jessica C. Hassel
    Antonia Dimitrakopoulou-Strauss
    Cancer Immunology, Immunotherapy, 2019, 68 : 297 - 303
  • [26] Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?
    Sachpekidis, Christos
    Larribere, Lionel
    Kopp-Schneider, Annette
    Hassel, Jessica C.
    Dimitrakopoulou-Strauss, Antonia
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (02) : 297 - 303
  • [27] Prognostic Value of Baseline 18F-FDG PET/CT to Predict Brain Metastasis Development in Melanoma Patients
    Kalantari, Forough
    Mirshahvalad, Seyed Ali
    Hoellwerth, Magdalena
    Schweighofer-Zwink, Gregor
    Huber-Schoenauer, Ursula
    Hitzl, Wolfgang
    Rendl, Gundula
    Koelblinger, Peter
    Pirich, Christian
    Beheshti, Mohsen
    CANCERS, 2024, 16 (01)
  • [28] Influence of 18F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma
    Susann-Cathrin Schüle
    Thomas Kurt Eigentler
    Claus Garbe
    Christian la Fougère
    Konstantin Nikolaou
    Christina Pfannenberg
    European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 : 482 - 488
  • [29] Influence of 18F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma
    Schuele, Susann-Cathrin
    Eigentler, Thomas Kurt
    Garbe, Claus
    la Fougere, Christian
    Nikolaou, Konstantin
    Pfannenberg, Christina
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (03) : 482 - 488
  • [30] False Negative and False Positive Findings with 18F-FDG PET/CT in Malignant Melanoma
    Liszkay, G.
    Kasler, M.
    Gilde, K.
    Fejos, Z.
    Lengyel, Z.
    Borbola, K.
    Schmidt, E.
    Borbely, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S442 - S442